Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study
暂无分享,去创建一个
C. Cooper | A. Díez-Pérez | J. Albanell | S. Servitja | I. Tusquets | N. Arden | X. Nogués | D. Prieto-Alhambra | L. Garrigós | M. K. Javaid
[1] A. Díez-Pérez,et al. Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer. , 2012, Breast.
[2] Karen A Gelmon,et al. Exemestane for breast-cancer prevention in postmenopausal women. , 2011, The New England journal of medicine.
[3] M. Ellis,et al. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial , 2011, Breast Cancer Research and Treatment.
[4] A. Avenell,et al. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative limited access dataset and meta-analysis , 2011, BMJ : British Medical Journal.
[5] JoAnn E. Manson,et al. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know , 2010, The Journal of clinical endocrinology and metabolism.
[6] A. Díez-Pérez,et al. Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study , 2011, Breast Cancer Research and Treatment.
[7] Jack Cuzick,et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. , 2010, The Lancet. Oncology.
[8] J. Griggs,et al. American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. , 2010, Journal of oncology practice.
[9] A. Díez-Pérez,et al. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer. , 2010, Maturitas.
[10] J. Simpson,et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. , 2010, JAMA.
[11] J. Mackey,et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] S. Cummings,et al. Serum 25-Hydroxyvitamin D and the Risk of Hip and Nonspine Fractures in Older Men , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[13] U. Dafni,et al. Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial , 2010, Breast Cancer Research.
[14] J B Wong,et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials , 2009, BMJ : British Medical Journal.
[15] D. Kiel,et al. Dietary Calcium and Serum 25‐Hydroxyvitamin D Status in Relation to BMD Among U.S. Adults , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[16] R. Chlebowski,et al. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study , 2009, Breast Cancer Research and Treatment.
[17] E John Orav,et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. , 2009, Archives of internal medicine.
[18] E. Perez,et al. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC , 2009, Breast Cancer Research and Treatment.
[19] R. Greil,et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. , 2008, The Lancet. Oncology.
[20] A. LaCroix,et al. Serum 25-Hydroxyvitamin D Concentrations and Risk for Hip Fractures , 2008, Annals of Internal Medicine.
[21] J. Forbes,et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] P. Neven,et al. Effective inhibition of aromatase inhibitor‐associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole , 2008, Cancer.
[23] M. Beckmann,et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Doughty. A review of the BIG results: the Breast International Group 1-98 trial analyses. , 2008, Breast.
[25] Jack Cuzick,et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. , 2008, The Lancet. Oncology.
[26] A. Howell,et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. , 2008, Cancer treatment reviews.
[27] E. Barrett-Connor,et al. Calcium and vitamin D intake influence bone mass, but not short-term fracture risk, in Caucasian postmenopausal women from the National Osteoporosis Risk Assessment (NORA) study , 2008, Osteoporosis International.
[28] C. Cooper,et al. Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. , 2007, Rheumatology.
[29] P. Lønning,et al. Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial , 2007, The Lancet.
[30] J. Forbes,et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] S. Cawthorn,et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. , 2007, The Lancet. Oncology.
[32] Michael Gnant,et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial , 2005, The Lancet.
[33] C. Cooper,et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial , 2005, The Lancet.
[34] M Baum,et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.
[35] James N Ingle,et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] M. Salmerón,et al. Predicción de la ingesta total de calcio a través del consumo de lácteos en la población adulta de España. Estudio INDICAD 2001 , 2004 .
[37] R. Doll,et al. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial , 2003, BMJ : British Medical Journal.